<div id="readability-page-1"><div><p>M Stanley issued a report updating its forecasts for SBP GROUP (01177.HK)<span> </span><span> +0.070 (+1.403%)  </span> <span> Short selling $129.05M; Ratio 14.748%  </span>  to incorporate the newly in-licensed bepirovirsen (HBV ASO), which is expected to start contributing revenue from 2027. At the same time, based on management guidance, the broker removed its assumption of dividend income from Sinovac LS starting from 2026. As a result, EPS forecasts for 2026 to 2028 were lowered by 8%, 7% and 7%, respectively. In addition, the broker adjusted its working capital and capital expenditure assumptions to better reflect recent operating trends. The TP was cut from HKD8.3 to HKD7.8. Rating Overweight. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)</p></div></div>

01177

513120

<p>M Stanley updated its forecast for SBP GROUP, cutting the target price from HKD8.3 to HKD7.8 while maintaining an Overweight rating. The revision incorporates revenue expectations from the newly licensed bepirovirsen starting in 2027 and removes dividend assumptions from Sinovac LS from 2026. Consequently, EPS forecasts for 2026-2028 were lowered by 7-8%, and working capital and capex assumptions were adjusted to reflect recent trends.</p>

AASTOCKS News

SINOVAC BIOTECH LTD

SBP GROUP

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

iShares Biotechnology ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Huaan Hang Seng Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

VanEck Biotech ETF

Direxion S&P Biotech Bear 3X

SPDR S&P Health

Penghua SSE STAR Biology and Medicine ETF

VG Health

ChinaAMC SSE Health Care ETF Initiating Fund

Proshares Ultra Nasdaq Biotech

Guotai SSE STAR Brand Name Drug ETF

SPDR S&P Biotech

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

China Southern Hang Seng Biotech ETF(QDII)

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Dacheng CSI All Share Health Care Equipment and Services ETF

Health Care Select Sector SPDR

Penghua CSI HK Connect Health Care Composite ETF

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

iShares Global Healthcare

Ark Genomic Revolution ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Pharma

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts SBP GROUP  TP to HKD7.8, Rating Overweight